摘要
目的系统评价丹参川芎嗪注射液联合血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体拮抗剂(ACEI/ARB)类药物治疗糖尿病肾病的有效性及安全性。方法检索中国知网、万方数据库、维普数据库、中国生物医学文献数据库、Pub Med、Embase、Cochrane Library、中国临床试验注册中心、Clinical Trials. gov数据库,收集丹参川芎嗪注射液联合ACEI/ARB类药物治疗糖尿病肾病的随机对照试验,对照组采取基础治疗联合ACEI/ARB类药物治疗;观察组在对照组基础上加用丹参川芎嗪注射液治疗。检索范围为建库至2021年1月,采用Rev Man 5.3软件进行Meta分析。结果共纳入12篇随机对照试验。观察组干预糖尿病肾病的总有效率高于对照组,差异有统计学意义(相对危险度=1.21,95%置信区间:1.13~1.29,P <0.001);观察组在改善患者血尿素氮、血肌酐、尿白蛋白排泄率等方面均优于对照组(均P <0.05)。2组均未见严重不良反应。结论丹参川芎嗪注射液联合ACEI/ARB类药物干预糖尿病肾病疗效较好,安全性较高。
Objective To systematically evaluate the efficacy and safety of salvia miltiorrhizae and ligustrazine hydrochloride injection combined with angiotensin converting enzyme inhibitor/angiotensin Ⅱ receptor blocker( ACEI/ARB) drugs in the treatment of diabetic nephropathy( DN). Methods Randomized controlled trials( RCTs) of salvia miltiorrhizae and ligustrazine hydrochloride injection combined with ACEI/ARB drugs in the treatment of DN were retrieved from China National Knowledge Infrastructure,Wanfang database,China Science and Technology Journal database,China Biology Medicine disc,Pub Med,Embase,Cochrane Library,Chinese Clinical Trial Registry and Clinical Trials. gov database. The control group was treated with basic treatment combined with ACEI/ARB drugs,and the observation group was treated with salvia miltiorrhizae and ligustrazine hydrochloride injection on the basis of the control group. The search scope was from the construction of the databases to January 2021. Rev Man 5. 3 was used for Meta-analysis. Results A total of 12 RCTs were included in the study. The total effective rate of the observation group was higher than that of the control group( risk ratio =1. 21,95% confidence interval: 1. 13-1. 29,P < 0. 001). The observation group was better than the control group in improving blood urea nitrogen,blood creatinine and urinary albumin excretion rate( all P < 0. 05). No serious adverse reactions were reported in both group. Conclusion Salvia miltiorrhizae and ligustrazine hydrochloride injection combined with ACEI/ARB drugs is effective and safe in the treatment of DN.
作者
王紫雯
荆鲁
李梓荣
杨俏丽
李金埕
覃锦
刘尚建
Wang Ziwen;Jing Lu;Li Zirong;Yang Qiaoli;Li Jincheng;Qin Jin;Liu Shangjian(Department of Nephrology and Endocrinology,Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Department of Medicine,Eye Hospital,China Academy of Chinese Medical Sciences,Beijing 100040,China)
出处
《中国医药》
2021年第10期1552-1557,共6页
China Medicine
基金
国家重点研发计划(2019YFC1710101)。
关键词
糖尿病肾病
丹参川芎嗪注射液
血管紧张素转换酶抑制剂
血管紧张素Ⅱ受体拮抗剂
系统评价
Diabetic nephropathy
Salvia miltiorrhizae and ligustrazine hydrochloride injection
Angiotensin converting enzyme inhibitor
AngiotensinⅡreceptor blocker
Systematic review
